CHRYSALIS-2: positive Phase 1b results demonstrate efficacy of amivantamab, lazertinib and chemotherapy combination in NSCLC

Results of the Phase 1b CHRYSALIS-2 study, presented at ESMO Annual Congress 2021 (16 Sept–21 Sept), show that the durable responses previously observed in EGFR-mutant non-small-cell lung cancer (NSCLC) patients treated with the amivantamab (Rybrevant®) and lazertinib (Leclaza®) combination are not affected by the addition of chemotherapy to the regimen. Osimertinib (Tagrisso®) is currently approved for use as a first-line treatment option in metastatic NSCLC patients whose tumors have an EGFR exon 19 deletion or L858R mutations. Despite the positive results of the pivotal FLAURA Phase III trial, which led to the approval of osimertinib, progression is still common and...